Neurotropic Tyrosine Receptor Kinase (NTRK) is a type of biomarker for cancer therapy and can be found in over 25 different types of cancer. NTRK gene fusions can be detected with a number of biomarker tests including NGS (Next Generation Sequencing). This is the only way to identify people who may be eligible for therapies that target these mutations. OrigiMed has one of the clinical databases with information on gene fusion. OriFusion is a patented technique, in partnership with Bayer, to detect specific gene fusions which allows treatment with targeted therapies such as Entrectinib. Companion Diagnostics (CDx) is a testing panel that screens for hundreds of gene sequences to be compared against known matches, which then allows for other specific targeted therapies to be used.